Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
RegulatoryapprovedRhapsido®Positive
AI Analysis
Summary
Novartis announced FDA approval of Rhapsido® (remibrutinib) for symptomatic dermographism, marking the first approved treatment for this condition and expanding the drug's indication beyond its prior use in chronic spontaneous urticaria.
Outcome Details
FDA approval as first treatment for symptomatic dermographism (SD), expanding use beyond chronic spontaneous urticaria (CSU)
Importance:8/10
Sentiment:
0.95
FDA approvalfirst-in-classdermatologylabel expansionremibrutinib
Related Companies
Read the original article
Published by yahoo_finance on October 7, 2026 3:45 PM